Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing
Descripción general
Resumen del artículo
This guideline recommends adjusting proton pump inhibitor (PPI) dosing based on a patient's CYP2C19 genotype to optimize efficacy and minimize adverse effects. Patients with genotypes predicting lower PPI exposure (rapid metabolizers) may benefit from higher doses, while those with genotypes predicting higher exposure (intermediate and poor metabolizers) may benefit from lower doses, especially during long-term therapy.
Explícamelo como si tuviera cinco años
Scientists found that some people's bodies break down stomach medicine differently. So, doctors might give you more or less medicine depending on how fast your body uses it, to make sure it works best.
Posibles conflictos de intereses
JAJ consults for United Health Group on pharmacogenomics implementation. SAS is employed by Sema4, a for-profit genetic testing company. DLT is employed by Translational Software, another for-profit genetic testing company offering pharmacogenetic testing. As an Associate Editor, Sara Van Driest was not involved in the review process.
Limitaciones identificadas
Explicación de la calificación
This paper offers valuable, clinically relevant guidance on PPI dosing based on CYP2C19 genotype. While limited by its focus on first-generation PPIs and Asian populations, it addresses an important clinical need and is well-supported by existing evidence. The disclosed COIs are noted but do not appear to significantly compromise the integrity of the work.
Conviene saber
Este es el análisis de Starter. Paperzilla Pro verifica cada cita, investiga los antecedentes de los autores y las fuentes de financiación, y utiliza razonamiento avanzado con IA para ofrecer información más exhaustiva.
Explorar Pro →